"Designing Growth Strategies is in our DNA"
Region : Global | Published Date: Upcoming | Report ID: FBI101275| Status : Pipeline
Autism, also referred to as Autism Spectrum Disorder (ASD), is used to refer to a complex neurobehavioral condition which has a broad range of symptoms which challenges such as social skills, speech, and nonverbal communication and repetitive behaviors. Some of the indicators of autism include persistent preference of solitude, avoidance of eye contact, loss of previously acquired speech or social skills, difficulty in understanding others’ emotions, restricted interests, delayed language development, and repetitive behaviors.
Autism can be caused by a variety of factors which include genetic risk factors such as autism that runs in families, advanced ages of the child’s parents, pregnancy and birth complications, the pregnancies that are spaced less than a year apart and the differences in brain biology of the child. For the treatment and management of the symptoms of autism, an approach including various types of treatment is often adopted. In terms of medications, Risperidone (Risperdal) is the only FDA approved the drug for the treatment of autism spectrum disorder (ASD) in children. But medical professionals often prescribe other medications such as anti-depressants to deal with the symptoms. Therapies such as play therapies, behavioral therapies, and sensory therapies can be administered.
Pharmaceutical companies and various research institutes have been focusing on studying and developing new treatment options for Autism. For instance; Balovaptan (RO5285119), which is being studied by F. Hoffmann-La Roche Ltd, is currently in phase-2 clinical trials for the Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants with Autism Spectrum Disorder (ASD).
To get details on market share, speak to our analyst
At present around 73% of the pipeline candidates for Autism are in the phase-1 and phase-2 stage combined. Majority of the studies are sponsored by industry and governmental institutions.
The report on ‘Autism – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Autism. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Autism.
The report on ‘Autism – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.